PAF-HEFT (Permanent Atrial Fibrillation in Heart Failure Trial)
NCT ID: NCT00839566
Last Updated: 2025-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
12 participants
INTERVENTIONAL
2008-11-30
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimising Pacing Therapy, Integrated Medical Therapy, and Catheter AbLation for Atrial Fibrillation in Heart Failure Trial
NCT07238452
CAtheter-Based Ablation of Atrial Fibrillation Compared to Conventional Treatment in Patients With Heart Failure With Preserved Ejection Fraction
NCT05508256
APAF: Assessment of Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation
NCT00111527
Radiofrequency Ablation (RFA) Versus Antiarrhythmic Drug Treatment in Paroxysmal Atrial Fibrillation
NCT00133211
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
NCT04160000
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AV ablation
Ablation
AV-node ablation
Rate control
Rate control by drugs
Rate Control
Rate control by drug
Sinus rhythm
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ablation
AV-node ablation
Rate Control
Rate control by drug
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* QRS time ≥150ms LBB
* NYHA classification ≥ NYHA III
* permanent (\> 6 months) Atrial Fibrillation
* sinus rhythm (control group)
* Condition after Implantation of a Medtronic CRT device
* written informed consent
Exclusion Criteria
* mitral incompetence (2. degree)
* no compliance
* participation in another study
* pregnancy
* patients with AV node
* patients after heart transplant or those who are on the transplant list
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic
INDUSTRY
Medtronic Cardiac Rhythm and Heart Failure
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian Perings, MD
Role: PRINCIPAL_INVESTIGATOR
marien Hospital Luenen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Professor Dr. med. Christian Perings
Lünen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CEN_G_CA_9
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.